Manuel Bello Segura, MD
Endocrinology, Diabetes & Metabolism · Indianapolis, INNPI 1659774669
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $26,600 of the $43,830 with a category attached, or 60.7%. Lilly USA, LLC accounts for 69.7% of it on its own, with 51 other manufacturers making up the rest. 2025 is the largest year on record at $34,862, more than ten times the $508 reported in 2019.
Across 734 payments — averaging $59.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$31K
- Medtronic$2K
- Dexcom, Inc.$1K
- AstraZeneca$1K
- Amgen$953
- Corcept Therapeutics$800
- plus $7K from 46 others
What the payments were for
- Speaking & faculty fees$26,60061%
- Travel & lodging$3,3518%
- Food & beverage$13,85332%
- Education$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEPBOUND$27,035
- MINIMED 780G$1,064
- iLet Bionic Pancreas$326
- FARXIGA$236
- CRENESSITY$193
- Strensiq$113
- JARDIANCE$113
- iLet Insulin Infusion Kit Inset$109
- iLet Insulin Infusion Kit Contact Detach$109
- LENVIMA$102
How this compares
$43,830 in reported general payments places this provider in the 85th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
See all endocrinology, diabetes & metabolism providers in Indiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 768 | $1,022,504 |
| OzempicSemaglutide | 276 | $379,267 |
| TrulicityDulaglutide | 98 | $151,705 |
| JardianceEmpagliflozin | 112 | $129,859 |
| FarxigaDapagliflozin Propanediol | 121 | $126,435 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 63 | $85,048 |
| Repatha SureclickEvolocumab | 55 | $63,014 |
| Xigduo XrDapaglifloz Propaned/Metformin | 61 | $47,832 |
| TymlosAbaloparatide | 15 | $45,079 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $33,438 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 28 | $32,504 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 176 | $31,442 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 17 | $20,897 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $19,921 |
| Tresiba Flextouch U-100Insulin Degludec | 20 | $18,672 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Baqsimi, Humalog | $30,555 | $1,187,849898 claims |
| Novo NordiskOzempic, Novolog | $682 | $385,450299 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $261 | $228,594191 claims |
| AstraZenecaFarxiga | $1,254 | $126,435121 claims |
| Radius Health, Inc.Tymlos | $467 | $45,07915 claims |
| AbbVieSynthroid, Creon | $398 | $27,166193 claims |
| MerckJanumet Xr | $37 | $20,89717 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $224 | $7,107560 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
Other endocrinology, diabetes & metabolism in Indianapolis
- Ernest AsamoahIndianapolis$959K
- Hisham AllababidiIndianapolis$195K
- Michael EconsIndianapolis$74K
- Carmella Evans-MolinaIndianapolis$55K
- Moazzam HabibIndianapolis$29K
- James EdmondsonIndianapolis$10K
- James ScheidlerIndianapolis$8K
- Cary MariashIndianapolis$6K
- Jayender ChintaparthiIndianapolis$5K
- Munro PeacockIndianapolis$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.